Gallo M - Search Results

1

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.

Gallo M, De Luca A, Maiello MR, D'Alessio A, Esposito C, Chicchinelli N, Forgione L, Piccirillo MC, Rocco G, Morabito A, Botti G, Normanno N. Gallo M, et al. Transl Lung Cancer Res. 2017 Aug;6(4):486-498. doi: 10.21037/tlcr.2017.05.07. Transl Lung Cancer Res. 2017. PMID: 28904891 Free PMC article. Review.

2

The role of the EGFR signaling in tumor microenvironment.

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. De Luca A, et al. Among authors: gallo m. J Cell Physiol. 2008 Mar;214(3):559-67. doi: 10.1002/jcp.21260. J Cell Physiol. 2008. PMID: 17894407 Review.

3

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.

Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S. Normanno N, et al. Among authors: gallo m. Breast Cancer Res Treat. 2008 Nov;112(1):25-33. doi: 10.1007/s10549-007-9830-2. Epub 2007 Nov 30. Breast Cancer Res Treat. 2008. PMID: 18060492

4

A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells.

Bevilacqua S, Gallo M, Franco R, Rossi A, De Luca A, Rocco G, Botti G, Gridelli C, Normanno N. Bevilacqua S, et al. Among authors: gallo m. Lung Cancer. 2009 Jul;65(1):123-5. doi: 10.1016/j.lungcan.2009.01.019. Epub 2009 Mar 3. Lung Cancer. 2009. PMID: 19261349

5

Target-based therapies in breast cancer: current status and future perspectives.

Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F. Normanno N, et al. Among authors: gallo m. Endocr Relat Cancer. 2009 Sep;16(3):675-702. doi: 10.1677/ERC-08-0208. Epub 2009 Jun 12. Endocr Relat Cancer. 2009. PMID: 19525314 Review.

6

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N. D'Alessio A, et al. Among authors: gallo m. Breast Cancer Res Treat. 2010 Sep;123(2):387-96. doi: 10.1007/s10549-009-0649-x. Epub 2009 Nov 28. Breast Cancer Res Treat. 2010. PMID: 19946741

7

Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells.

De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N. De Luca A, et al. Among authors: gallo m. J Cell Physiol. 2011 Aug;226(8):2131-8. doi: 10.1002/jcp.22548. J Cell Physiol. 2011. PMID: 21520065

8

Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.

Gallo M, De Luca A, Lamura L, Normanno N. Gallo M, et al. Ann Oncol. 2012 Mar;23(3):597-604. doi: 10.1093/annonc/mdr159. Epub 2011 May 6. Ann Oncol. 2012. PMID: 21551002 Free article.

9

Pharmacokinetic evaluation of zoledronic acid.

De Luca A, Lamura L, Gallo M, Daniele G, D'Alessio A, Giordano P, Maiello MR, Pergameno M, Perrone F, Normanno N. De Luca A, et al. Among authors: gallo m. Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):911-8. doi: 10.1517/17425255.2011.585156. Epub 2011 May 13. Expert Opin Drug Metab Toxicol. 2011. PMID: 21563999 Review.

10

Zoledronic acid in early-stage breast cancer.

Normanno N, De Luca A, Gallo M, Lamura L, Perrone F. Normanno N, et al. Among authors: gallo m. Lancet Oncol. 2011 Oct;12(11):991. doi: 10.1016/S1470-2045(11)70216-9. Lancet Oncol. 2011. PMID: 21968222 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,656 results

Search Page